



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2003/07/15
(87) Date publication PCT/PCT Publication Date: 2004/01/22
(85) Entrée phase nationale/National Entry: 2004/12/09
(86) N° demande PCT/PCT Application No.: EP 2003/007657
(87) N° publication PCT/PCT Publication No.: 2004/007535
(30) Priorité/Priority: 2002/07/17 (02015907.5) EP

(51) Cl.Int.⁷/Int.Cl.⁷ C07K 7/56, A61K 38/12, C07K 14/36
(71) Demandeur/Applicant:
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG,
DE
(72) Inventeurs/Inventors:
POTTERAT, OLIVIER, DE;
STREICHER, RUEDIGER, DE;
WAGNER, KLAUS, DE;
MAURER, TILL, DE;
MACK, JUERGEN, DE;
PETERS, STEFAN, DE
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : OLIGOPEPTIDES BICYCLIQUES ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR
DU GLUCAGON
(54) Title: BICYCLIC OLIGOPEPTIDES AND THEIR USE AS GLUCAGON RECEPTOR ANTAGONISTS

(57) **Abrégé/Abstract:**

The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, which essentially consists of (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the -carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007535 A1

- (51) International Patent Classification⁷: **C07K 7/56**, (74) Common Representative: **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG**; Binger Strasse 173, 55216 Ingelheim (DE).
A61K 38/12, C07K 14/36
- (21) International Application Number: PCT/EP2003/007657 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 15 July 2003 (15.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02015907.5 17 July 2002 (17.07.2002) EP (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **POTTERAT, Olivier** [CH/DE]; Steinäckerstrasse 7, 88441 Mittelbiberach (DE). **STREICHER, Rüdiger** [DE/DE]; Kastanienweg 31, 88400 Biberach (DE). **WAGNER, Klaus** [DE/DE]; Erlenweg 31/1, 88447 Warthausen (DE). **MAURER, Till** [DE/DE]; Eicherweg 26, 89613 Oberstadion (DE). **MACK, Jürgen** [DE/DE]; Amriswilstrasse 7, 88400 Biberach (DE). **PETERS, Stefan** [DE/DE]; Ulmenweg 12, 88400 Biberach (DE).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: BICYCLIC OLIGOPEPTIDES AND THEIR USE AS GLUCAGON RECEPTOR ANTAGONISTS

(57) Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, which essentially consists of (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the -carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.

WO 2004/007535 A1

BICYCLIC OLIGOPEPTIDES AND THEIR USE AS GLUCAGON RECEPTOR ANTAGONISTS

Description of the Invention

- 5 The invention relates to bicyclic oligopeptides or esters thereof which have the capability to inhibit the glucagon receptor.

Background to the invention

The US patent US 5,919,926 discloses bicyclic depsipeptides which are produced by
10 fermentation of a specific marine actinomycete (CNB-091) in saltwater-based media. These bicyclic depsipeptides are taught to be useful as anti-biotic and anti-inflammatory agents.

Glucagon is a 29-amino acid peptide hormone produced by the A-cells in the pancreas and is a major counterregulatory hormone to insulin in the maintenance of glucose
15 homeostasis. Insulin promotes the uptake of glucose by cells, especially muscle cells and prevents an excessive breakdown of glycogen stored in liver and muscle. As an antidiabetic hormone essential for lowering blood sugar, insulin is a powerful hypoglycemic agent. In most instances, the actions of glucagon are contrary to those of insulin. Its main function is to stimulate hepatic glucose production. The activated
20 glucagon receptor signals via the cAMP-PKA signalling cascade and increases the rate of glucose de novo synthesis via gluconeogenesis and the liberation of glucose from glycogen stores via glycogenolysis.

Diabetes is a complex disease characterized by hyperglycemia resulting from defect insulin secretion, insulin action, or both. The metabolic complications of diabetes - hyperglycemia
25 and ketosis - are associated with a relative or absolute increase in the ratio of glucagon to insulin. Thus, glucagon is a hyperglycemic factor which causes blood sugar to increase. Accordingly, a means of treating diabetes is to block the glucagon receptor with a suitable

- 2 -

antagonist, thereby inhibiting glucose production by the liver and reducing glucose levels in the patient.

Several publications disclose peptidic and non-peptidic glucagon receptor antagonists (McCormick et al., Curr. Pharm. Des. 7, 1451 (2001) for review). Inhibition of glucagon-stimulated glucose production in humans has been reported for Bay 27-9955 (Petersen et al., Diabetologia 44, 2018 (2001)).

It has now been surprisingly discovered that certain bicyclic oligopeptides are highly efficient inhibitors of the glucagon receptor and are therefore of potential use in the treatment or prophylaxis of hyperglycaemia and in particular in the treatment of *diabetes mellitus (Type I and Type II)*.

These bicyclic oligopeptides are also indicated to be of potential use for the treatment or prophylaxis of other diseases including IGT (impaired glucose tolerance), insulin resistance syndromes, hyperinsulinemia, hyperlipidemia, dyslipidemia, arteriosclerosis, cardiovascular diseases, hypertension, cardiac hypertrophy, increased renal albumin clearance, glucagonomas, pancreatitis, obesity, gastrointestinal disorders, certain eating disorder and as a therapy to increase gastric acid secretion.

Summary of the Invention

Accordingly, the invention relates to novel bicyclic oligopeptides or esters thereof having the capability to inhibit the glucagon receptor, which essentially consists of

- (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, in particular the β -carboxylate group of an aspartic acid or the γ -carboxylate group of a glutamic acid, and
- (b) a second cyclic group which is formed by an amide bonding of an amino acid with the α -carboxylate group of said diacid amino acid, in particular aspartic or glutamic acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a).

- 3 -

Another aspect of the invention are the bicyclic oligopeptides according to the invention for the use as medicament.

Furthermore, the invention relates to a pharmaceutical composition comprising at least one bicyclic oligopeptide according to the present invention and a pharmacologically
5 acceptable carrier and to the use of a bicyclic oligopeptide according to the present invention for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.

Another aspect of the invention is a method for the treatment or prevention of diseases, in which glucagon receptors are involved, which method comprises administration of an
10 effective amount of a bicyclic oligopeptide according to the present invention to a patient in need thereof.

Detailed description of the invention

The term "second carboxylate group" as used hereinbefore and hereinbelow with respect to
15 a diacid amino acid relates to the carboxylate group which is not attached to the carbon atom which bears the amino group. Preferably it relates to the β - or γ -carboxylate group of an aspartic or glutamic acid.

The term "diacid amino acid" as used hereinbefore and hereinbelow with respect to a the amino acid which forms the first cyclus with the N-terminal amino acid via an amide bond
20 relates to an amino acid which exhibits two carboxylate groups, preferably aspartic or glutamic acid.

In a preferred embodiment the invention relates to a bicyclic oligopeptide, which comprises at least 3 amino acid moieties between the N-terminal amino acid and the said diacid amino acid; and/or which comprises at least 4 amino acid moieties between the said
25 diacid amino acid and the C-terminal cysteine.

- 4 -

Furthermore preferred are such bicyclic oligopeptides, which are obtainable by isolation from an *Actinomyces*, preferably a *Streptomyces* sp., in particular the microorganism which is deposited pursuant to the Budapest Treaty under the accession number DSM 14996, and optionally derivatized subsequently by esterification.


- 5 Preferably, the *Streptomyces* sp. are cultured in a medium comprising soy flour, glucose, sodium chloride, CaCO_3 , KH_2PO_4 , glucose-casein pepton, yeast extract, meat extract and water at a pH-value from 6.5 to 7.5, in particular from 6.8 to 7.3 at temperatures from 25 to 35 °C, in particular at about 28 °C.

The bicyclic oligopeptide is preferably obtainable from said fermentation broth by
10 extraction with a polar organic solvent, preferably an alcohol such as methanol and ethanol or dimethylsulfoxide (DMSO) or mixtures thereof, most preferably a mixture of methanol and DMSO, wherein the methanol to DMSO ratio ranges from 1000 : 1 to 10 : 1, in particular from 500 : 1 to 100 : 1. The extract is preferably concentrated *in vacuo* and the concentrated extract is enriched by chromatography, in particular by preparative HPLC
15 using acetonitrile and ammonium acetate buffer (pH 3-5), in particular in form of a gradient of 2 - 60% of acetonitrile and ammonium acetate buffer, as eluent. The enriched product is preferably purified by column chromatography using an alcohol, preferably methanol as eluent.

The optional esterification is carried out using standard esterification methods, preferably
20 by reaction of the bicyclic oligopeptide with trimethylsilyldiazomethane, in particular in form of a 2N solution in hexane in a polar organic solvent, preferably acetonitrile or methanol or a mixture thereof. The reaction mixture is preferably purified by preparative HPLC and freeze dried.

Particularly preferred are bicyclic oligopeptides, which are characterized by formula I,

- 5 -



wherein

Xaa¹ represents a N-terminal α -amino acid, in particular selected from the group consisting of glycine, alanine, leucine, norleucine and valine, in particular glycine;

5 Xaa² represents a diacid amino acid, preferably an aspartic or glutamic acid, in particular aspartic acid,

Xaa³, Xaa⁴ and Xaa⁵ each independently represent an α -amino acid, preferably selected from the group consisting of glycine, alanine, isoleucine, leucine, norleucine, valine, proline, threonine, asparagine, tryptophan and serine

10 m, n and q each independently represent an integer from 2 to 12, preferably wherein the sum of $m + n + q$ is an integer from 11 to 22, in particular from 13 to 17; and

R represents a hydrogen atom or a C₁₋₆ alkyl group.

Most particularly preferred are the compounds of formula I, wherein

15 Xaa³ each independently represent an α -amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and tryptophan, in particular glycine, leucine, proline and tryptophan;

Xaa⁴ each independently represent an α -amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and serine, in particular proline and serine; and

20 Xaa⁵ each independently represent an α -amino acid selected from the group consisting of glycine, alanine, isoleucine, leucine, norleucine, valine, proline, threonine, asparagine, tryptophan and serine, in particular glycine, alanine, isoleucine, proline, threonine, asparagine, tryptophan and serine,


m represents an integer from 3 to 6, in particular 4;

25 n represents an integer from 2 to 4, in particular 2;

q represents an integer from 6 to 12, in particular 9; and

R represents a hydrogen atom or a methyl group.

Most preferred is a bicyclic nonadecapeptide or ester thereof, characterized by the following sequence:



In addition to the method to isolate the bicyclic oligopeptides from *Streptomyces* sp., the compounds of the present invention can be synthetically prepared from amino acids applying standard solid phase peptide synthesis.

The linker is selected in the way that upon cleavage from the resin the peptide is liberated containing a carboxylic acid at the C-terminus. Therefore, preferably the so called 2-chlorotrityl-resin bearing a 2-chlorotrityl linker or the so called Wang-resin containing the 4-hydroxymethylphenoxybenzyl-linker, which are both commercially available, are applicable. Due to known side reactions in peptide synthesis with C-terminal cysteine residues like diketopiperazine formation it is recommended to start with commercially available H-Cys(Acm)-2-chlorotrityl resin (Nova Biochem).

The stepwise peptide assembly is preferably performed under standard conditions using N α -Fmoc-protected (PG1) amino acids and in situ activation reagents like TBTU. The side chains in the amino acids are protected as usual for Fmoc/tBu-peptide synthesis, e.g. tBu for serine and threonine, trityl for asparagine, Boc for tryptophan (PG2).

- 7 -


The cysteine residues should be protected by protecting groups, which can be selectively removed at the end of the synthesis. For this purpose preferably the acetamidomethyl (ACM) group (PG3) which is stable towards TFA is selected.

For the on-resin cyclisation of the diacid amino acid, in particular Asp and the N-terminal
5 amino acid, in particular Gly, the side chain carboxylic acid of the diacid amino acid, in particular aspartic acid need to be selectively deprotected without cleaving the peptide from the solid support. Therefore, an allylester protecting group is most suitable.

The peptide assembly is as a rule performed under standard conditions until completion of the coupling of the N-terminal Fmoc-protected amino acid, in particular Fmoc-glycine
10 residue. For the cyclisation of N-terminal amino acid, in particular glycine-1 and the diacid amino acid, in particular aspartic or glutaric acid it is necessary to deprotect the amino and the acid function of both amino acids, respectively. The allylester of aspartic or glutaric acid can be cleaved applying palladium catalysts, preferably $\text{Pd}(\text{PPh}_3)_4$ in presence of a nucleophile, preferably dimedone, barbituric acid or dimethylamine. The Fmoc-group of
15 the N-terminal group, in particular glycine can be removed as a rule with 20% piperidine in DMF. The ring formation can be achieved with standard peptide coupling reagents, preferably TBTU.

- 8 -

The cleavage of the peptide from the polymer can be performed with trifluoroacetic acid (TFA), preferably 50 % TFA in dichloromethane. Using these conditions, the trityl-, tBu- and Boc-protecting groups in the peptide are also removed. At this stage, it is recommended to purify the peptide by reversed phase HPLC. The deprotection of the
 5 cysteine residues and disulfide formation is preferably carried out with mercury(II)-salts, preferably mercury(II)-acetate, or iodine. The following reaction scheme illustrates the solid phase peptide synthesis of the bicyclic oligopeptide according to the present invention:



As indicated hereinbefore the present invention also provides a bicyclic oligopeptide or an
 10 ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular diseases and certain eating disorders.

- 9 -

A bicyclic oligopeptide or an ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

- 5 Accordingly, the present invention also provides a pharmaceutical composition comprising a bicyclic oligopeptide or an ester thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

As used herein the term `pharmaceutically acceptable` embraces compounds, compositions
10 and ingredients for both human and veterinary use: for example the term `pharmaceutically acceptable salt` embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral
15 administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

- 20 In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium
25 lauryl sulphate or sucrose.

- 10 -

Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.01 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.

The present invention further provides a method for the treatment and/or prophylaxis of
5 hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the bicyclic oligopeptide or the ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

The present invention further provides a method for the treatment of hyperlipidaemia in a
10 human or non-human mammal, which comprises administering an effective, non-toxic, amount of a bicyclic oligopeptide or an ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition
15 hereinbefore defined, and this forms a particular aspect of the present invention.

In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the bicyclic oligopeptide or the ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described above, one to six times a day in a
20 manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.

In the treatment and/or prophylaxis of hyperglycaemic non-human mammals, especially dogs, the active ingredient may be administered by mouth, usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg
25 to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.

- 11 -

The bicyclic oligopeptide or the ester thereof may be administered alone or in combination with another active agent, which is conventionally used in the treatment or prophylaxis of hyperglycaemia, hyperlipidemia, obesity and hypertension.

In particular the compounds according to the invention may be used in combination with
5 one or more antidiabetic agents. The antidiabetic agents comprise biguanides, glucosidase inhibitors, PPARgamma modulators, dual PPARalpha/gamma agonists, RXR modulators, SGLT2 inhibitors, aP2 inhibitors, insulin sensitizers, GLP-1 or mimetics, DPPIV inhibitors, PTP-1B inhibitors, GSK-3 inhibitors and/or a metiglinide. The antidiabetic agent is specifically metformin, glyburide, glibenclamide, glimepiride, glypiride, glipizide,
10 chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide, nateglinide, and/or exendin-4.

The compounds of the invention may be used in combination with lipid modulating agents. The lipid modulating agents comprise HMG CoA reductase inhibitors, fibric acid derivatives, CETP inhibitors, ACAT inhibitors, MTP inhibitors, squalene cyclase and
15 squalene synthetase inhibitors, LXR modulators and/or bile acid sequestrants. The lipid modulating agent is especially pravastatin, lovastatin, fluvastatin, simvastatin, atorvastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate, cholestyramine, colestipol, probucol, nicotinic acid, implitapide and/or avasimibe.

The compounds of the invention may be used in combination with anti-obesity agents. The
20 anti-obesity agents comprise lipase inhibitors, serotonin and dopamine reuptake inhibitors, beta3 adrenergic agonists, MCH antagonists, MC4 agonists, leptin or mimetics, fatty acid oxidation upregulators and/or fatty acid and triglyceride synthesis inhibitors. The anti-obesity agent is especially orlistat, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, famoxin and/or mazindol.

25 The compounds of the invention may be used in combination with cardiovascular agents. The cardiovascular agents comprise alpha-adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, antiarrhythmic agents, anticoagulants, antiplatelet agents, thrombolytic agents, beta-adrenergic blockers, calcium antagonists, centrally acting hypertensive agents, diuretics, neuronal and ganglionic blockers, and/or

- 12 -

vasodilators. The cardiovascular agent is specifically doxazosin, prazosin, terazosin, benazepril, captopril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, quinapril, ramipril,trandolapril, irbesartan, losartan, valsartan, telmisartan, disopyramide, flecainide, ibutilide, lidocaine, mexiletine, moricizine, procainamide, propafenone, quinidine, 5 tocainide, amiodaron, bretylium, anisindione, dicumarol, heparin, warfarin, abciximab, anagrelide, aspirin, clopidogrel, dipyridamole, ticlopidine, alteplase, anistreplase, reteplase, streptokinase, urokinase, nadolol, propranolol, sotalol, timolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, acebutolol, carteolol, penbutolol, pindolol, carvedilol, labetalol, amlodipine, bepridil, diltiazem, felodipine, isradipine, mibefradil, nicardipine, 10 nifedipine, nimodipine, verapamil, clonidine, guanabenz, guanfacine, methyl dopa, bumetanide, ethacrynic acid, furosemide, torsemide, bendroflumethiazide, benthiazide, chlorothiazide, chlorthalidone, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, metolazone, polythiazide, quinethazone, trichlormethiazide, amiloride, spironolactone, guanadrel, guanethidine, mecamlamine, reserpine, cyclandelate, fenoldopam, hydralazine, 15 minoxidil, pentoxifylline, phenoxybenzamine, erythrityl tetranitrate, isosorbide, nitroglycerin, and/or nitroprusside.

The dosages regimens for the treatment of other diseases (e.g. hypertension, cardiovascular disease and eating disorders) will generally be those mentioned above in relation to hyperglycaemia.

20 In a further aspect the present invention provides the use of a bicyclic oligopeptide or an ester thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.

The present invention also provides the use of a bicyclic oligopeptide or an ester thereof 25 and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.

A major advantage of the bicyclic oligopeptide according to the invention is its high glucagon receptor affinity and its surprising stability in physiological media.

- 13 -

The examples that follow serve to illustrate the present invention. They are to be understood as being merely illustrative given solely as examples without restricting the invention to their content.

5 EXAMPLE 1

Preparation and isolation of bicyclic nonadecapeptid of the following sequence



1. Preparation

(a) Pre-culture:

100 mL of the following culture medium are prepared in 300 ml Erlenmeyer flasks with 4
10 chicanes:

soy flour 15.0 g, glucose 15.0 g, sodium chloride 5.0 g, CaCO₃ 1.0 g, KH₂PO₄ 0.3 g and water ad 1000 ml, pH 6.9. A small slice of agar with a well cultivated stem of streptomycetes DSM 14996 serves as inoculum. The flasks are agitated 48 hours at 160 U/min and 28°C.

15 (b) Fermentation

250 ml of a glucose-casein pepton medium are prepared in 1L Erlenmeyer flasks:

Glucose 20.0 g, casein pepton 4.0 g, yeast extract 0.5 g, meat extract 4.0 g, sodium chloride 2.5 g, CaCO₃ 3.0 g, water ad 1000 ml, pH 7.2. Each of the flasks is inoculated with 20 ml of the pre-culture and maintained 120 Std. at 160 U/min and 28 °C.

20 2. Isolation:

(a) Extraction

The mycelia and the lyophilisate from 6 L culture broth are combined and extracted with a mixture of MeOH (2l and 1l) and DMSO (2 x 5 ml) twice. The extract is concentrated to a

- 14 -

remaining volume of about 40 ml (extract A) *in vacuo*. The precipitate thereof is centrifuged off and dissolved in a mixture of MeOH (6 ml) and DMSO (3 ml), which is added to the concentrated extract (extract A).

(b) Chromatography

- 5 The resulting extract A is purified by preparative HPLC in portions of 1.8 ml with a C-18 Nova-Pack column (Waters, 6 μ m, 2,5 x 10 cm) with pre-column (2,5 x 1.0 cm). A gradient of 5 - 51% CH₃CN against 1 mM ammonium acetate buffer (pH 4) within 16 min serves as eluant. The flow rate is 20 ml/min. The peptide is detected by UV absorption at 220 nm. Subsequently, the enriched peptide is purified on a Sephadex LH-20 column (2,5 x 70 cm)
- 10 in portions of 100 mg using MeOH (1,0 ml/min) as eluent, to yield 25 mg/L of the pure desired product.

EXAMPLE 2

Esterification of the compound of example 1

- A mixture of trimethylsilyldiazomethane (2N solution in hexane, 0.048ml, 0.096mmol)
- 15 and acetonitril/methanol (9/1, 0.85ml) is added to a mixture of the bicyclic nonadecapeptide prepared in example 1 (23.7mg, 0.0116mmol) and 0.85ml DMSO. After 20h another portion of trimethylsilyldiazomethane (2N solution in hexane, 0.048ml, 0.096mmol) is added. The reaction is then controlled by LC-MS indicating that 75% of the acid (retention time=5,84 min, (M-H)-:2035, (M-2H)2-:1017) has been converted to the
- 20 methyl ester (retention time=5,96 min, (M+H)+:2051, (M+2H)2+:1026). The reaction mixture is purified by preparative HPLC and freeze dried.

The compounds of examples 1 and 2 show the following properties:

Example 1: C₉₅H₁₂₅N₂₃O₂₄S₂ MW2035.87 (monoisotopic) 2037.3 (average)

Example 2: C₉₆H₁₂₇N₂₃O₂₄S₂ MW2049.89 (monoisotopic) 2051.3 (average)

- 25 and the following solubilities:

Example 1

Buffer pH 3.0: 0.003 mg/ml

- 15 -

Buffer pH 7.4: 0.120 mg/ml
Buffer pH 10.0: 0.092 mg/ml

5 Example 2

Buffer pH 3.0: 0.003 mg/ml
Buffer pH 7.4: 0.002 mg/ml
Buffer pH 10.0: 0.004 mg/ml

10

EXAMPLE 3

Glucagon binding assay

Binding of peptides to the glucagon receptor was assayed in a competition binding-assay using a membrane fraction containing the cloned human glucagon receptor and
15 radiolabeled glucagon.

The cDNA coding for the human glucagon receptor was cloned into expression vector pcDNA3.1 (Invitrogene). Baby hamster kidney cells (BHK-21(C-13) cells (ATCC)) were transfected with the expression construct for the human glucagon receptor and a stably transfected cell clone was isolated after selection with G-418 (Gibco).

20 Plasma membranes containing the human glucagon receptor were prepared from stably transfected BHK-21 cells. Cells were grown to confluence, washed and detached with ice cold PBS buffer (Gibco), containing 0.05% EDTA and collected in PBS buffer. The cells were collected by centrifugation and suspended in 20 volumes of ice-cold tris buffer (10 mM tris/HCl, pH7.2; 0.01 mM PMSF (Phenylmethylsulfonyl fluoride)) and incubated for
25 90 minutes. All further steps were performed at 4°C. The suspension was lysed completely by 10 strokes of a Dounce homogenizer. Nuclei and cellular debris were separated by centrifugation for 10 min. at 500g. The supernatant was then centrifuged at 100,000g for 35 minutes. The precipitated membranes were suspended in incubation buffer (50 mM tris/HCl, 100 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, 0.2% bovine serum albumin, pH
30 7.2), aliquoted and stored at -80°C.

After thawing BHK cell membranes expressing the human glucagon receptor were re-suspended in incubation buffer completed with 0.01 mM PMSF.

- 16 -

For measuring competition with glucagon binding, 20 µg of the membrane suspension were incubated for 60 minutes in covered microtiter plates (Optiplate, Packard Instruments) with 50.000 cpm 125I-glucagon (Amersham Pharmacia), and one concentration of the test compound in a total volume of 100 µl. The protein-bound radioactivity is separated from
5 unbound ligand by filtration and washing on a Multiscreen-Vakuumfiltrationsystem (Millipore) using GC/B filters (Packard) and measured after addition of 20 µl Microscint 20 in a topcount scintillation counter (Packard). The non-specific binding is defined as radioactivity bound in the presence of 1 µM glucagon (Wherl GmbH).

Accordingly an IC₅₀ value can be calculated from the results obtained in the above test
10 method. The bicyclic oligopeptides show the following activities:

Example 1: IC₅₀ = 100 nM;

Example 2: IC₅₀ = 135 nM;

EXAMPLE 4

15 **Metabolic stability:**

Incubations with preparations of microsomes and cytosol and with plasma under conditions as described below are suitable to investigate the metabolic stability of test compounds (e.g. oxidative metabolism reactions and hydrolysis by esterases). The metabolic stability of the test compounds of examples 1 and 2 is investigated in liver
20 microsomes and cytosol of humans, dogs and rats and in plasma of humans and rats.

Stability with microsomes and cytosol

Incubations of test compounds (final concentration: 1 µM) are performed with liver microsomes and cytosol (0.5 mg protein/ml) in Tris buffer (Tris-(hydroxymethyl)-aminomethane) pH 7.4 (0.1 M) containing magnesium chloride (5 mM) at 37°C for up to
25 45 min in a total volume of 100 µl. The reaction is initiated by addition of β-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 1 mM) and terminated by addition of acetonitrile. After vortex mixing and centrifugation the supernatants are analyzed.

- 17 -

Stability in plasma

Incubations of test substrates (final concentration: 1 μ M) are performed with human and rat plasma (heparin) containing 0.1 M Tris buffer pH 7.4. The reaction is initiated by addition of the test compound at 37°C for up to 45 min and terminated by addition of
 5 acetonitrile. After vortex mixing and centrifugation the supernatants are analyzed.

Analytic

The samples are analyzed by on-line solid phase extraction and reversed phase HPLC coupled to electro-spray ionization tandem mass spectrometry. The measurements are performed on a triple quad mass spectrometer Quattro II (Micromass, Manchester, UK).
 10 The instrument operates at nominal mass resolution in SIR-mode. The analytes are quantified by detection of their quasimolecular ions $[M+2H]^{2+}$ m/z 1019 (Example 1) and m/z 1026 (Example 2).

The following stabilities are obtained

15 Substrate (initial conc.): 1 μ M

Half-lives, ($t_{1/2}$ [min])

Species	Rat			Dog		Human		
	Micros	Cytosol	Plasma	Micros	Cytosol	Micros	Cytosol	Plasma
Example 1	stable	stable	stable	stable	stable	stable	stable	182
Example 2	stable	73	stable	stable	140	stable	122	180

EXAMPLE 5

Examples of pharmaceutical formulations

	A)	<u>Tablets</u>	<u>per tablet</u>
5		active substance (Example 1)	50 mg
		lactose	170 mg
		corn starch	260 mg
		polyvinylpyrrolidone	15 mg
10		magnesium stearate	5 mg
			<hr/> <hr/> 500 mg

The finely ground active substance, lactose and some of the corn starch are mixed together.

15 The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

20	B)	<u>Tablets</u>	<u>per tablet</u>
		active substance (Example 1)	40 mg
		corn starch	210 mg
25		lactose	65 mg
		microcrystalline cellulose	40 mg
		polyvinylpyrrolidone	20 mg
		sodium-carboxymethyl starch	23 mg
		magnesium stearate	<u>2 mg</u>
30			400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.

35 The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

- 19 -

C)	<u>Coated tablets</u>	<u>per coated tablet</u>
	Active substance (Example 1)	5 mg
5	Corn starch	41.5 mg
	Lactose	30 mg
	Polyvinylpyrrolidone	3 mg
	Magnesium stearate	<u>0.5 mg</u>
		80 mg

10

The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45°C and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax..

D)	<u>Capsules</u>	<u>per capsule</u>
20	Active substance (Example 1)	25 mg
	Corn starch	283.5 mg
	Magnesium stearate	<u>1.5 mg</u>
		310 mg

25

The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.

30 E) Ampoule solution

	active substance (Example 1)	0,5 mg
	sodium chloride	50 mg
	water for inj.	5 ml

35

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from

- 20 -

pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 0,5 mg, 2,5 mg and 5,0 mg of active substance.

5 F) Suppositories

Active substance (Example 2)	30 mg
Solid fat	<u>1670 mg</u>
	1700 mg

10

The solid fat is melted. The ground active substance is homogeneously dispersed at 40 °C. It is cooled to 38 °C and poured into slightly chilled suppository moulds.

PCT

Original (for SUBMISSION) - printed on 15.07.2003 11:37:24 AM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-2	International Application No.	PCT/EP 03 / 07 6 57
0-3	Applicant's or agent's file reference	1-1368-PCT-B

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	13
1-2	line	13
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	15 May 2002 (15.05.2002)
1-3-4	Accession Number	DSMZ 14996
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the International application: (yes or no)	yes	F. v.d. Krogt 12. 08. 2003
0-4-1	Authorized officer		

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE


INTERNATIONAL FORM

Boehringer Ingelheim Pharma KG

Birkendorfer Str. 65

88397 Biberach a.d. Riss

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: ST 21660	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 14996
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2002-05-15 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-05-21

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPESTER VERTRAG ÜBER DIE INTERNATIONALE
ANERKENNUNG DER HINTERLEGUNG VON MIKROORGANISMEN
FÜR DIE ZWECKE VON PATENTVERFAHREN


INTERNATIONALES FORMBLATT

Boehringer Ingelheim Pharma KG

Birkendorfer Str. 65

88397 Biberach a.d. Riss


LEBENSFÄHIGKEITSBESCHEINIGUNG
ausgestellt gemäß Regel 10.2 von der unten angegebenen
INTERNATIONALEN HINTERLEGUNGSSTELLE

I. HINTERLEGER		II. KENNZEICHNUNG DES MIKROORGANISMUS	
Name: Boehringer Ingelheim Pharma KG Birkendorfer Str. 65 Anschritt: 88397 Biberach a.d. Riss		Von der INTERNATIONALEN HINTERLEGUNGSSTELLE zugeteilte EINGANGSNUMMER: DSM 14996 Datum der Hinterlegung oder Weiterleitung ¹ : 2002-05-15	
III. LEBENSFÄHIGKEITSBESCHEINIGUNG			
Die Lebensfähigkeit des unter II genannten Mikroorganismus ist am 2002-05-15 ² geprüft worden. Zu diesem Zeitpunkt war der Mikroorganismus <input checked="" type="checkbox"/> ³ lebensfähig <input type="checkbox"/> ³ nicht mehr lebensfähig			
IV. BEDINGUNGEN, UNTER DENEN DIE LEBENSFÄHIGKEITSPRÜFUNG DURCHGEFÜHRT WORDEN IST ⁴			
V. INTERNATIONALE HINTERLEGUNGSSTELLE			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Anschritt: Mascheroder Weg 1b D-38124 Braunschweig		Unterschrift(en) der zur Vertretung der internationalen Hinterlegungsstelle befugten Person(en) oder des (der) von ihr ermächtigten Bediensteten:  Datum: 2002-05-21	

- ¹ Angabe des Datums der Ersthinterlegung. Wenn eine erneute Hinterlegung oder eine Weiterleitung vorgenommen worden ist, Angabe des Datums der jeweils letzten erneuten Hinterlegung oder Weiterleitung.
² In den in Regel 10.2 Buchstabe a Ziffer ii und iii vorgesehenen Fällen Angabe der letzten Lebensfähigkeitsprüfung.
³ Zutreffendes ankreuzen.
⁴ Ausfüllen, wenn die Angaben beantragt worden sind und wenn die Ergebnisse der Prüfung negativ waren.

Patent Claims

1. A bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, which essentially consists of
 - 5 (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and
 - (b) a second cyclic group which is formed by an amide bonding of an amino acid with the α -carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-
10 terminal cysteine and a cysteine group within the first cyclic group (a).
2. Bicyclic oligopeptide according to claim 1, which comprises at least 3 amino acid moieties between the N-terminal amino acid and the said diacid amino acid.
3. Bicyclic oligopeptide according to claim 1 or 2, which comprises at least 4 amino acid moieties between the said diacid amino acid and the C-terminal cysteine.
- 15 4. Bicyclic oligopeptide according to one of the claims 1 to 3, obtainable by Isolation from a *Actinomyces* sp and optionally followed by esterification.
5. Bicyclic oligopeptide according to claim 4, which is obtainable from *Streptomyces* sp.
6. Bicyclic oligopeptide according to claim 5, which is obtainable from
20 *Streptomyces* deposited under the accession number DSM 14996.
7. Bicyclic oligopeptide according to one of the claims 1 to 6, which is characterized by formula I,



wherein

Xaa¹ represents a N-terminal α-amino acid,

Xaa² represents a diacid amino acid,

- 5 Xaa³, Xaa⁴ and Xaa⁵ each independently represent an α-amino acid,
 m, n and q each independently represent an integer from 2 to 12, and
 R represents a hydrogen atom or a C₁₋₆ alkyl group.

8. Bicyclic oligopeptide of formula I according to claim 7, wherein

10 Xaa¹ represents a N-terminal α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine and valine,

Xaa² represents an aspartic or glutamic acid,

Xaa³ each independently represent an α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and tryptophan,

15 Xaa⁴ each independently represent an α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and serine, and

Xaa⁵ each independently represent an α-amino acid selected from the group consisting of glycine, alanine, isoleucine, leucine, norleucine, valine, proline, threonine, asparagine, tryptophan and serine,

m represents an integer from 3 to 6,


20 n represents an integer from 2 to 4,

q represents an integer from 6 to 12, and

R represents a hydrogen atom or a methyl group.

9. Bicyclic oligopeptide according to any one of the claims 1 to 8, wherein each amino acid exists in the (L)-configuration.

10. Bicyclic nonadcapeptide according to any one of the claims 1 to 9, characterized by the following sequence:



wherein

the amino group of Gly¹ is linked with the β-carboxylate group of Asp⁹ via an amide
10 group, and
the thiole groups of the cysteines Cys⁶ and Cys¹⁹ are linked via a disulfide bridge.

11. Bicyclic oligopeptide according to any of the claims 1 to 10 for the use as medicament.

12. Pharmaceutical composition comprising at least one bicyclic oligopeptide
15 according to any of the claims 1 to 10 and a pharmacologically acceptable carrier.

13. Pharmaceutical composition according to claim 12 comprising at least one bicyclic oligopeptide according to any of the claims 1 to 10 and an active ingredient selected from the group consisting of antidiabetic agents, lipid modulating agents, anti-obesity agents and cardiovascular agents.

14. Pharmaceutical composition according to claim 13, wherein the antidiabetic agent is selected from the group comprising biguanides, glucosidase inhibitors, PPARgamma modulators, dual PPARalpha/gamma agonists, RXR modulators, SGLT2 inhibitors, aP2 inhibitors, insulin sensitizers, GLP-1 or mimetics, DPPIV inhibitors, PTP-1B inhibitors, GSK-3 inhibitors and a metiglinide.

25 15. Pharmaceutical composition according to claim 13 or 14 wherein the antidiabetic agent is selected from the group consisting of metformin, glyburide, glibenclamide, glimepiride, glypiride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide, nateglinide, and exendin-4.

16. Use of a bicyclic oligopeptide according to any of the claims 1 to 11 or of a pharmaceutical composition according to any one of claims 12 to 15 for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.

5 17. Use of a bicyclic oligopeptide according to claim 16 for the preparation of a medicament for the treatment or prevention of *diabetes mellitus*.

18. A method for the treatment or prevention of diseases, in which glucagon receptors are involved, which method comprises administration of an effective amount of a bicyclic oligopeptide according to any of the claims 1 to 10 to a patient in need thereof.